Page last updated: 2024-10-28
hexamethonium and ADDH
hexamethonium has been researched along with ADDH in 1 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ueno, K | 1 |
| Togashi, H | 1 |
| Matsumoto, M | 1 |
| Ohashi, S | 1 |
| Saito, H | 1 |
| Yoshioka, M | 1 |
Other Studies
1 other study available for hexamethonium and ADDH
| Article | Year |
|---|---|
Alpha4beta2 nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Attention Deficit Disorder with Hyperactivity; Beh | 2002 |